Levi & Korsinsky notifies investors that it has commenced an investigation into Sangamo Therapeutics, Inc. (NASDAQ: SGMO) concerning potential violations of the federal securities laws.
Sangamo announced on December 30, 2024, that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be returning after the development and commercialization rights to giroctocogene fitelparvovec after deciding not to pursue commercialization of the asset, which is in phase 3. Sangamo stated in a press release announcing this development, that it was "surprised and extremely disappointed by Pfizer's decision" to end the collaboration so close to anticipated Biologics License Application and Marketing Authorisation Application submissions for giroctocogene fitelparvovec, which the Company had expected to occur in early 2025. The collaboration and license agreement with Pfizer will terminate effective April 21, 2025, at which time Pfizer will be required to transition the giroctocogene fitelparvovec program back to Sangamo. Following this news, Sangamo's stock price fell during intraday trading on December 31, 2024.
If you suffered a loss on your Sangamo Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





